ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 119

Laser Flare Photometery in the Pediatric Rheumatology Clinic as a Screening Tool for Juvenile Idiopathic Arthritis Associated Uveitis

Kaleo Ede1, Michael Shishov2, Elisa Wershba2, Nikita Goswami2, Sabrina Gorry2, Malin Jospeh2, Lucia Mirea2 and James O'neil2, 1Phoenix Children's Hosptial; University of Arizona College of Medicine- Phoenix, Phoenix, AZ, 2Phoenix Children's Hospital, Phoenix, AZ

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: Disease Activity, Eye Disorders, Juvenile idiopathic arthritis, physical examination

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, March 31, 2023

Title: Posters: Clinical and Therapeutic II

Session Type: Poster Session B

Session Time: 5:00PM-6:00PM

Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in childhood, affecting 1 to 22 per 100,000 children. JIA-associated uveitis is known to occur in up to 12% of JIA patients in the United States. Visual complications are present in up to 2/3 of patients, with blindness in as many as 30-50% of affected eyes. The gold standard to diagnose JIA-associated uveitis is slit lamp examination by trained eye specialists using a subjective grading scale (Standardization of Uveitis Nomenclature or SUN) to quantify anterior segment inflammation. Recently, laser flare photometery (LFP) has been used in multiple studies as an objective, non-invasive, and quantitative method to measure anterior chamber inflammation. LFP has been used by ophthalmologists to monitor JIA-associated uveitis patients as well as other forms of pediatric non-infectious chronic anterior uveitis.

The purpose of this study is to investigate if LFP can be used in a pediatric rheumatology office setting to diagnose patients with JIA-associated uveitis.

Methods: This observational study was approved by the Phoenix Childrens IRB, and enrolled patients aged 4-16 years diagnosed with JIA based on the 2001 ILAR classification criteria during 2019-2022. Exclusion criteria were having a history of JIA-associated uveitis or any other form of uveitis, as well as history of pacemaker placement. All patients underwent at least one evaluation of both eyes using a Kowa FM-600 laser flare photometer, as well as a standard slit lamp examination by optometry or ophthalmology during routine clinical care. Data collected at patient visits included demographics, JIA characteristics, treatment medications, LFP readings, and AC cell grade scored by SUN grading system. Data were summarized using descriptive analyses and the uveitis false positive rate was calculated along with 95% confidence interval.

Results: Subjects included 58 pediatric patients diagnosed with JIA with data obtained for 138 eyes at 69 visits. The mean age was 8.4 years (range: 1.2-16.3 years) at diagnosis and 11.9 (range: 4.8-16.5) years at enrollment. Of the 58 patients, the majority 43 (74.1%) were female (table 1). Most common JIA subtypes included 19 (32.8%) patients with persistent oligoarticular JIA, and 12 (20.7%) with RF negative polyarticular JIA. At enrollment, 15 patients (25.9%) were on no medications, with 26 (44.8%) on methotrexate, 22 (37.9%) on adalimumab, 6 (10.3%) on tocilizumab, and 5 (8.6%) on etanercept (table Treatment at baseline included methotrexate (44.8%), adalimumab (37.9%), etanercept (8.6%), tocilizumab (10.3%) and none (25.9%) (table 2). During the study period, no eye exams detected active uveitis based on slit lamp exam with a SUN grade over 0. However, of the 135 LFP readings, 131 (97.0%) were normal, yielding a false positive rate of 3% (95% CI of 0.8%, 7.4%) (table 3).

Conclusion: Laser Flare Photometry is a non-invasive tool that can be utilized in the pedaitric rheumatology clinic to evaluate for JIA-associated uveitis. There is a low false positive rate of LFP when compared with standard slit lamp exam. Future studies will examine LFP to monitor uveitis activity in patients with JIA-associated uveitis to help guide treatment decisions.

Supporting image 1Table 1. Demographic characteristic data at baseline

Supporting image 2Table 2. JIA subtype and treatment characteristic data at baseline

Supporting image 3Table 3. Uveitis activity based on slit lamp exam versus Laser Flare Photometry (LFP)


Disclosures: K. Ede: None; M. Shishov: AbbVie/Abbott, 6, Novartis, 6; E. Wershba: None; N. Goswami: None; S. Gorry: None; M. Jospeh: None; L. Mirea: None; J. O'neil: None.

To cite this abstract in AMA style:

Ede K, Shishov M, Wershba E, Goswami N, Gorry S, Jospeh M, Mirea L, O'neil J. Laser Flare Photometery in the Pediatric Rheumatology Clinic as a Screening Tool for Juvenile Idiopathic Arthritis Associated Uveitis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/laser-flare-photometery-in-the-pediatric-rheumatology-clinic-as-a-screening-tool-for-juvenile-idiopathic-arthritis-associated-uveitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/laser-flare-photometery-in-the-pediatric-rheumatology-clinic-as-a-screening-tool-for-juvenile-idiopathic-arthritis-associated-uveitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology